Tirzepatide, a GLP-1/GIP dual agonist, has demonstrated mean body weight reductions of approximately 20.9% over 72 weeks in adults with obesity
Current Pharmaceutical Design, 26(25), 28732883
Additionally, in phase 2 studies in people with MASH and liver fibrosis, survodutide not only significantly improved liver steatosis, but also led to histologic improvement of MASH without worsening fibrosis in 4362% of participants, versus 14% with placebo [41]
We look forward to working with regulators as they evaluate this first-of-its-kind medicine." In TRIUMPH-2, all three studied doses of retatrutide (4 mg, 9 mg, and 12 mg) delivered substantial weight loss and improved glycemic control at 80 weeks in adults with type 2 diabetes and obesity or overweight
Furthermore, your lower back and your knees take a terrible beating every time you walk up a flight of stairs
Andya, D